Banner - Home

Utility

Injectafer® (ferric carboxymaltose injection) is an iron replacement product indicated for the treatment
of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory
response to oral iron, or in adult patients with non-dialysis dependent chronic kidney disease.1

Learn more about choosing Injectafer.

 
Patient Profile Icon Review content tailored to your patient type
 
Injectafer Mechanism of Action Video SEE INJECTAFER EDUCATIONAL VIDEOS
Watch videos
Infusion Center Pindrop Icon Infusion Center Locator

When oral iron fails, it’s time to consider IV iron

When oral iron fails, it’s time to consider IV iron

Choose Injectafer, the only FDA-approved IV iron that delivers up to 1500 mg in 1 course of therapy. Injectafer is dosed in 2 administrations of 750 mg separated by at least 7 days.1 100% of IV iron is delivered into the patient's bloodstream.

Choose Injectafer, the only FDA-approved IV iron that delivers up to 1500 mg in 1 course of therapy. Injectafer is dosed in 2 administrations of 750 mg separated by at least 7 days.1  100% of IV  iron is delivered into the patient's bloodstream.

Take two 750 mg doses of Injectafer 7 days apart for a total course up to 1500 mg. IV infussion over at least 15 minutes or slow IV push over 7.5 minutes Benefits of Injectafer IV Iron Administration

Take two 750 mg doses of Injectafer 7 days apart for a total course up to 1500 mg. IV infussion over at least 15 minutes or slow IV push over 7.5 minutes Benefits of Injectafer IV Iron Administration

Injectafer treatment may be repeated if iron deficiency anemia reoccurs. Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment (see Important Safety Information).

*For adult patients weighing less than 50 kg (110 lb), give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course of treatment.

When administered via IV infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not <2 mg of iron per mL, and administer over at least 15 minutes. When administered as a slow IV push, give at the rate of approximately 100 mg (2 mL) per minute.

More About Injectafer

Injectafer is unlike any other iv iron

The most studied
IV iron in the world2‡

#1 IV iron therapy in
worldwide sales||

#1 IV iron by volume
among oncologists and
gastroenterologists2¶#

100%
dextran-free2**

Source: Trialtrove®| Informa, 2019.

§Based on Swiss Franc (CHF) worldwide sales.

||Based on quarterly IQVIA® MIDAS® panel, Farma&Cia, GERs, DLI at wholesale acquisition costs, Q1-2019. Average 2018 exchange rates have been applied.

Source: Symphony Health Solutions PHAST® Non-Retail December 2018 - November 2019 (MAT November 2019).

#Source: IQVIA® IV Iron Landscape (Dx and CDM Data - July-Sep 2019).

**In Injectafer clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer.1

Help your patients access iron

InjectConnect Support Program InjectConnect Support Program

Injectafer Savings Program

Contact Daiichi Sankyo Access Central Contact info for Daiichi Sankyo Access Central. Visit DSIAccessCentral.com to download helpful resources. If you have an questions, call Daiichi Sankyo Access Central at 1-866-4-DSI-NOW. Monday through Friday, 9 am to 8 pm Eastern Time

Visit DSIAccessCentral.com
to download helpful resources. If you have any questions, call Daiichi Sankyo Access Central at 1-866-4-DSI-NOW Monday–Friday, 9:00 AM–8:00 PM ET.

 

 

Terms and Condition

Injectafer Savings Program — Terms and Conditions

  1. This offer is valid for commercially-insured as well as cash paying patients.
  2. Depending on insurance coverage, eligible insured patients may pay no more than $50 for Injectafer for the first dose and $0 for Injectafer for the second dose, up to a maximum savings limit of $500 per dose, a $1,000 program limit per course of therapy. Check with your pharmacist or healthcare provider for your copay discount. Patient out-of-pocket expense may vary.
  3. This offer is not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or private indemnity or HMO insurance plans that reimburse you for the entire cost of your prescription drugs. Patients may not use this card if they are Medicare-eligible and enrolled in an employer-sponsored health plan or medical or prescription drug benefit program for retirees.
  4. The offer is valid for 2 courses, or 4 doses, of an Injectafer prescription. An explanation of benefits statement must be faxed in prior to transacting on the account numbers for assistance. One enrollment is allowed per 12-month period.
  5. Daiichi Sankyo, Inc. reserves the right to rescind, revoke, or amend this offer without notice.
  6. Offer good only in the USA, including Puerto Rico, at participating pharmacies or healthcare providers.
  7. Void if prohibited by law, taxed, or restricted.
  8. This account number is not transferable. The selling, purchasing, trading, or counterfeiting of this account number is prohibited by law.
  9. This account number is not insurance.
  10. By redeeming this account number, you acknowledge that you are an eligible patient and that you understand and agree to comply with the terms and conditions of this offer.
  11. Qualified patients receiving Injectafer will be allowed a 60-day retroactive enrollment period to receive benefits under the program rules.

††Restrictions apply. See Terms and Conditions above.

‡‡The Injectafer Savings Program is only available for adults 18 years or older who are commercially insured or cash-paying patients. Please see full Terms and Conditions above.

§§Insurance out-of-pocket payment must be over $50. Other restrictions may apply. As of November 2019.

Patient Assistance Program – Program Eligibility

To be eligible for the program, patients must completely lack health insurance and be ineligible for public insurance or financing. The patient must also be a US citizen, legal entrant in the United States, or permanent resident. Proof of citizenship or legal residency may also be required. Patients must also meet income and other criteria as established by Daiichi Sankyo, Inc.

Important Safety Information

INDICATIONS

Injectafer® (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis dependent chronic kidney disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.

WARNINGS AND PRECAUTIONS

Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting. These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment. Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency and malnutrition. In most cases, hypophosphatemia resolved within three months.

Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment.

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.

In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.

In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.

ADVERSE REACTIONS

In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).

The following adverse reactions have been identified during post approval use of Injectafer. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions have been reported from the post-marketing spontaneous reports with Injectafer: cardiac disorders: tachycardia; general disorders and administration site conditions: chest discomfort, chills, pyrexia; metabolism and nutrition disorders: hypophosphatemia; musculoskeletal and connective tissue disorders: arthralgia, back pain, hypophosphatemic osteomalacia (rarely reported event); nervous system disorders: syncope; respiratory, thoracic and mediastinal disorders: dyspnea; skin and subcutaneous tissue disorders: angioedema, erythema, pruritus, urticaria.

You are encouraged to report Adverse Drug Events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Please see Full Prescribing Information.

References - Home